Innate Biotherapeutics has developed a unique platform that harnesses the power of engineered fungal carbohydrates, specifically beta-1,6-glucan, to stimulate the innate immune system. This innovative approach involves covalently linking these carbohydrates to tumor-targeting monoclonal antibodies, which not only attract pre-existing antibodies but also activate the complement system. This process recruits innate immune cells to target and eliminate tumor cells, effectively transforming the immunosuppressive tumor microenvironment into one that promotes immune activation. The company’s pre-clinical pipeline showcases a strong intellectual property portfolio and lead programs that have undergone extensive testing, including pilot toxicity studies in non-human primates.

The technology leverages both the innate and adaptive immune systems, marking a significant advancement in cancer immunotherapy. By coating cancer cells with beta-1,6-glucan, the immune system is signaled to respond as if there is a fungal infection, leading to a cascade of immune responses. This includes the recruitment and activation of neutrophils, which play a crucial role in initiating an inflammatory response and subsequently activating T-cells against tumor neo-antigens. Innate Biotherapeutics aims to provide effective treatments for a variety of solid and liquid tumors, with the potential for both monotherapy and combination therapies, thereby enhancing the efficacy of existing tumor-targeting antibodies.

United States

Innate Bio’s platform is based on an engineered fungal carbohydrate that stimulates the innate immune system—our body’s first response against fungal infections. These carbohydrates are covalently linked to tumor-targeting monoclonal antibodies, which attract pre-existing antibodies, activate the complement system, and ultimately recruit innate immune cells to kill the tumor cells. Innate Bio’s antibody-beta-1,6-glucan conjugate technology has been applied to several monoclonal antibodies targeting cancer peripheral proteins.

Innate Biotherapeutics

Company Details